Drug Type Monoclonal antibody |
Synonyms LDP, lesabelimab, ADG104 + [1] |
Target |
Action inhibitors |
Mechanism PDL1 inhibitors(Programmed death-ligand 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Kidney Neoplasms | Phase 2 | China | 07 Jan 2021 | |
Kidney Neoplasms | Phase 2 | China | 07 Jan 2021 | |
Muscle Invasive Bladder Carcinoma | Phase 2 | China | 07 Jan 2021 | |
Muscle Invasive Bladder Carcinoma | Phase 2 | China | 07 Jan 2021 | |
Penile Neoplasms | Phase 2 | China | 07 Jan 2021 | |
Penile Neoplasms | Phase 2 | China | 07 Jan 2021 | |
Advanced Renal Cell Carcinoma | Phase 2 | China | 11 Sep 2020 | |
Bladder Cancer | Phase 2 | China | 11 Sep 2020 | |
Relapsed Penile Carcinoma | Phase 2 | China | 11 Sep 2020 | |
Advanced cancer | Phase 1 | China | 30 May 2019 |